---
$id: https://graph.org.ai/products/commodity/51131735
$type: Product
source: UNSPSC
code: "51131735"
title: "Nupafant"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Nupafant

**UNSPSC Code**: 51131735
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C23H32N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02NKI0ARRJ, chemically known as n-(s)-1-ethoxy-methyl-3-methylbutyl-n-methyl-alpha-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)-p-toluenesulfonamide but generally known as nupafant, which bears US NIH Compound Identifier 3047797. European Medicines Agency schedules Nupafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09391MIG. The term NUPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). NUPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nupafant under HS 29350090 and SITC 51580. As of Q4 2014, NUPAFANT remains the US FDA Preferred Term for this commodity. Nupafant bears US NLM identifiers UMLS ID C1741717 and NCI Concept Code C81564. SMILES: S(=O)(=O)(N(COCC)C)C1C(CCC(C)C)CC(CN2C3C(NC2C)CNCC3)CC1.

